Patents by Inventor Timothy Middleton

Timothy Middleton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20150119319
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz
  • Phenanthridine macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8951964
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: February 10, 2015
    Assignees: AbbVie Inc., Enanta Pharmaceuticals, Inc.
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, David J. Grampovnik, Brian Green, Timothy Middleton, Todd Hopkins, Yat Sun Or
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8937041
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: January 20, 2015
    Assignee: AbbVie, Inc.
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz
  • PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20120295842
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: December 29, 2011
    Publication date: November 22, 2012
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, David J. Grampovnik, Brian Green, Timothy Middleton, Todd Hopkins, Yat Sun Or
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20120172291
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 5, 2012
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz